• Je něco špatně v tomto záznamu ?

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study

E. Bachy, JA. Estell, E. Van de Neste, R. Bouabdallah, J. Bargay, A. Delmer, B. Gelas-Dore, M. Gomes da Silva, O. Fitoussi, D. Belada, H. Maisonneuve, T. Intragumtornchai, T. Lamy, P. Dartigues, JF. Seymour, G. Salles,

. 2016 ; 91 (4) : 410-5.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027726

An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027726
003      
CZ-PrNML
005      
20161018095428.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.24305 $2 doi
024    7_
$a 10.1002/ajh.24305 $2 doi
035    __
$a (PubMed)26799234
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bachy, Emmanuel $u Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.
245    10
$a Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study / $c E. Bachy, JA. Estell, E. Van de Neste, R. Bouabdallah, J. Bargay, A. Delmer, B. Gelas-Dore, M. Gomes da Silva, O. Fitoussi, D. Belada, H. Maisonneuve, T. Intragumtornchai, T. Lamy, P. Dartigues, JF. Seymour, G. Salles,
520    9_
$a An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a kohortové studie $7 D015331
650    _2
$a lékové interakce $7 D004347
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x škodlivé účinky $x terapeutické užití $7 D019161
650    _2
$a folikulární lymfom $x diagnóza $x farmakoterapie $x mortalita $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Estell, Jane A $u Hematology Department, Concord Hospital, Concord, NSW, Australia.
700    1_
$a Van de Neste, Eric $u Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
700    1_
$a Bouabdallah, Réda $u Hematology Department, Institut Paoli Calmettes, Marseille, France.
700    1_
$a Bargay, Joan $u Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.
700    1_
$a Delmer, Alain $u Hematology Department, CHU De Reims, Reims, France.
700    1_
$a Gelas-Dore, Bénédicte $u Deparment of Biostatistics, Lysarc, Lyon, France.
700    1_
$a Gomes da Silva, Maria $u Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.
700    1_
$a Fitoussi, Olivier $u Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
700    1_
$a Belada, David $u Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.
700    1_
$a Maisonneuve, Hervé $u Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.
700    1_
$a Intragumtornchai, Tanin $u Hematology Department, Chulalongkorn University, Bangkok, Thailand.
700    1_
$a Lamy, Thierry $u Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.
700    1_
$a Dartigues, Peggy $u Hematology Department, Institut Gustave Roussy, Villejuif, France.
700    1_
$a Seymour, John Francis $u Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
700    1_
$a Salles, Gilles $u Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 91, č. 4 (2016), s. 410-5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26799234 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161018095832 $b ABA008
999    __
$a ok $b bmc $g 1166040 $s 952356
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 91 $c 4 $d 410-5 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Možnosti archivace